Patients must not have an organ allograft or other history of immune compromise; patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowed
Currently receiving systemic corticosteroids or other immunosuppressive medications or has a medical condition that requires the chronic use of corticosteroids; Note: inhaled and topical steroids are permitted
Diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within  days of first dose of study drug
Patients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent, except corticosteroids with a daily dosage equivalent to prednisone =<  mg; however, patients receiving corticosteroids must have been on a stable dosage regimen for a minimum of  weeks prior to the first treatment with everolimus; topical or inhaled corticosteroids are allowed
Chronic treatment with corticosteroids or other immunosuppressive therapy
Chronic treatment with corticosteroids or other immunosuppressive agents
Patients who have concurrent conditions resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agents
Chronic systemic therapy with immunosuppressive agents including corticosteroids.
Use of escalating or chronic supraphysiologic doses of corticosteroids or immunosuppressive agents (such as, cyclosporine). [Use of topical, ophthalmic, inhaled, and intranasal corticosteroids permitted].
Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids
Patients on immunosuppressive therapy including:\r\n* Systemic corticosteroid therapy for any reason; patients receiving inhaled or topical corticosteroids may participate
Patients who are on chronic treatment with corticosteroids or other immunosuppressive agents (topical or inhaled corticosteroids are allowed)
Ongoing immunosuppressive therapy other than corticosteroids.
Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Subjects may be using topical or inhaled corticosteroids.
Diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within  days of study registration
Chronic treatment with corticosteroids or other immunosuppressive agents
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Patients with graft versus host disease (GVHD) active < grade  who are on a stable dose of immunosuppressive therapy (tacrolimus, cyclosporine, or other) for >  weeks will be included; Note: subjects may be using systemic corticosteroids or topical or inhaled corticosteroids
Chronic treatment with high dose corticosteroids or other immunosuppressive agents; topical, inhaled, and low dose oral corticosteroids are allowed provided stable dosing for at least  weeks
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed, and treatment with low dose Decadron (=< mg daily) is allowed
Increasing or chronic treatment (>  days) with corticosteroids or another immunosuppressive agent
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
Patients on immunosuppressive therapy including:\r\n* Systemic corticosteroid therapy for any reason; patients receiving inhaled, intranasal or topical corticosteroids may participate
Patients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).
Chronic treatment with corticosteroids or other immunosuppressive agents
TREATMENT: Patients requiring chronic treatment with corticosteroids or other immunosuppressive agents are ineligible to receive everolimus (topical or inhaled corticosteroids are allowed)
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
Patients receiving chronic, systemic treatment with corticosteroids (more than  mg/day prednisone equivalent, see inclusion criteria) or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent are not eligible to participate in this study; topical or inhaled corticosteroids are allowed
Patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowed
Ongoing systemic immunosuppressive therapy other than corticosteroids.
Patients on immunosuppressive therapy including systemic corticosteroids.
A requirement for daily systemic corticosteroids for any reason; or other immunosuppressive or immunomodulatory agents; topical, nasal or physiologic corticosteroids are to be permitted
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within  days of first dose of study drug
Chronic treatment with corticosteroids or other immunosuppressive agents; note: topical or inhaled corticosteroids are allowed
Patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowed
Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of CLL or other conditions. Note: Subjects may be using topical or inhaled corticosteroids as therapy for comorbid conditions.
Patients receiving current treatment with corticosteroids or another immunosuppressive. Topical or inhaled corticosteroids are allowed.
Chronic system corticosteroids for any reason (inhaled corticosteroids are allowed); pre-medication for chemotherapy is acceptable
Chronic immunosuppressive therapies, including systemic corticosteroids
No concurrent condition resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agents
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
Concurrent condition resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agents
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent(Topical or inhaled corticosteroids are allowed)
Patients receiving immunosuppressive treatment as well as corticosteroids which cannot be discontinued at least  weeks before dosing.
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
Patients requiring chronic immunosuppressive therapy (including corticosteroids) for any medical condition
Patients with a diagnosis of immunodeficiency, or who are dependent on or have received systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment with the exception of topical corticosteroids and occasional inhaled corticosteroids, as indicated
Chronic treatment with systemic corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
EXPANSION COHORT ONLY: Chronic treatment with systemic corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Patients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).
Ongoing systemic immunosuppressive therapy other than corticosteroids
Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids (can be using topical or inhaled corticosteroids).
Ongoing immunosuppressive therapy other than corticosteroids
Active treatment with corticosteroids or other immunosuppressive agents
Chronic (treatment >  month) or ongoing treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Ongoing immunosuppressive therapy other than corticosteroids
Patients who require systemic corticosteroid or other systemic immunosuppressive therapy; immunosuppressive therapy must be stopped at least  days prior to enrollment; topical agents and/or inhaled corticosteroids are permitted
Currently receiving increasing or chronic treatment ( >  days) with corticosteroids (e.g. dexamethasone >  mg/day or other corticosteroids equivalent dose) or another immunosuppressive agent.
Patients requiring corticosteroids (other than inhaled) will be excluded
Ongoing immunosuppressive therapy, including systemic corticosteroids. Patients may be using topical or inhaled corticosteroids.
Systemic immunosuppressive agents (including corticosteroids) have not been received for at least  weeks
Increasing or chronic treatment (>  days) with corticosteroids or another immunosuppressive agent
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
Patient is currently receiving increasing or chronic treatment with corticosteroids or another immunosuppressive agent
Systemic corticosteroids for any reason (inhaled corticosteroids are allowed)
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; (topical or inhaled corticosteroids are allowed)
The patient requires concomitant chronic treatment (more than  consecutive days) with systemic corticosteroids or any other immunosuppressive agents.
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids, and treatment with low dose Decadron (=<  mg daily) are allowed
Patients requiring corticosteroids (other than inhaled) will be excluded
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Patients on chronic corticosteroids
Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or inhaled corticosteroids are allowed;